medigraphic.com
ISSN 2007-3194 (Print)
Órgano de difusión oficial del Instituto Materno Infantil del Estado de México

2023, Number 2

<< Back Next >>

Arch Inv Mat Inf 2023; 14 (2)

Neonatal renal injury secondary to maternal antihypertensive therapy: a case report

Rodríguez-Balderrama I, Castillo-Uvalle D, Cárdenas-Del CBG

Language: Spanish
References: 10
Page: 79-82
PDF size: 141.79 Kb.


ABSTRACT

Introduction: the kidney is the organ in charge of homeostasis in extrauterine life. The RAS (renin angiotensin system) has a fundamental role during fetal organogenesis and especially in kidney development. Renal failure can originate within the uterus, prenatal causes include maternal consumption of angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers (ARBs) and can also produce oligohydramnios, fetal growth restriction, among others. others. Case report: this is a newborn whose intrauterine growth restriction and oligohydramnios were detected at birth, who was subsequently admitted to the neonatal intensive care unit due to acute kidney injury. Conclusion: treatment with ARBs during the second and third trimester of pregnancy is associated with serious complications in the neonate from the prenatal period such as oligohydramnios, an hydramnios, renal failure, anuria, to mention a few.


REFERENCES

  1. Landau D, Shalev H, Shulman H, Barki Y, Maor E, Zmora E. Oligohydramnion, renal failure and no pulmonary hypoplasia in glomerulocystic kidney disease. Pediatr Nephrol. 2000; 14 (4): 319-321.

  2. García-Pérez CS, Cordero-González G. Función renal en el recién nacido. Perinatol Reprod Hum. 2011; 25 (3): 161-168.

  3. Hasbún J, Valdés RE, San Martín OA, Catalán MJ, Salinas QS, Parra CM. Efectos sobre la función renal fetal y neonatal del tratamiento con antagonistas del receptor de angiotensina II en el embarazo. Caso clínico. Rev Med Chile. 2008; 136 (2): 624-630.

  4. Coronado G, Rodríguez SC, Paredes G, Pinto LJ. Injuria renal fetal y neonatal: una complicación de la terapia antihipertensiva materna. Reporte de caso. Rev Ecuat Pediatr. 2019; 20 (2): 43-46.

  5. Baudin M, Herbez C, Guellec I, Dhombres F, Guilbaud L, Parmentier C et al. Predictive factors for survival in patients with oligohydramnios secondary to antenatal kidney disease. Pediatr Nephrol. 2023; 38 (6): 1783-1792.

  6. Loos S, Kemper MJ. Causes of renal oligohydramnios: impact on prenatal counseling and postnatal outcome. Pediatr Nephrol. 2018; 33: 541-545.

  7. Pérez-Iranzo A, Nos FA, Jarque BA, Maternal olmesartan exposure causing neonatal failure. BMJ Case Rep. 2017; 2017: bcr-2016218921.

  8. Bhat L, Bisht S, Khanijo K. Olmesartan intake during pregnancy leading to reversible renal failure and skull hypoplasia in a preterm newborn. Pediatr Oncall J. 2017; 14 (1): 13-14.

  9. Stojanovic V, Barisic N, Radovanovic T, Bjelica M, Milanovic B, Doronjski A. Acute kidney injury in premature newborns-definition, etiology, and outcome. Pediatr Nephrol. 2017; 32 (10): 1963-1970.

  10. Marchetto L, Sordino D, De Bernardo G, Trevisanuto D. Postnatal acute renal failure after fetal exposure to angiotensin receptor blockers. BMJ Case Rep. 2015; 2015: bcr2014207450.




2020     |     www.medigraphic.com